Compare GSHD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | WVE |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2018 | 2015 |
| Metric | GSHD | WVE |
|---|---|---|
| Price | $57.31 | $5.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $72.50 | $29.81 |
| AVG Volume (30 Days) | 588.9K | ★ 2.6M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $3,704,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | $85.67 |
| P/E Ratio | $51.83 | ★ N/A |
| Revenue Growth | 16.15 | ★ 149.43 |
| 52 Week Low | $33.68 | $5.02 |
| 52 Week High | $93.91 | $21.73 |
| Indicator | GSHD | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 45.35 |
| Support Level | $40.71 | $5.49 |
| Resistance Level | $77.70 | $6.48 |
| Average True Range (ATR) | 3.95 | 0.27 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 88.91 | 32.81 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.